Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium

Rhea-AI Summary

Precigen, Inc. (Nasdaq: PGEN) announced that its President and CEO, Helen Sabzevari, PhD, will join a virtual fireside chat on April 4, 2023, from 10:45 AM to 11:15 AM ET at Cantor's "The Future of Oncology" Virtual Symposium.

Specializing in innovative gene and cell therapies, Precigen aims to address urgent healthcare challenges in immuno-oncology, autoimmune disorders, and infectious diseases. Investors can find more details in the Events & Presentations section on Precigen's website.

GERMANTOWN, Md., March 28, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat on April 4, 2023 from 10:45 AM to 11:15 AM ET at Cantor's "The Future of Oncology" Virtual Symposium.

Details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations. 

Precigen: Advancing Medicine with Precision^™
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven M. Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com

Media Contacts:
Donelle M. Gregory
press@precigen.com

Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-a-virtual-fireside-chat-at-cantors-the-future-of-oncology-virtual-symposium-301782722.html

SOURCE Precigen, Inc.

FAQ

What is the date of Precigen's virtual fireside chat?

Precigen's virtual fireside chat will take place on April 4, 2023.

Who will represent Precigen at the Cantor Virtual Symposium?

Helen Sabzevari, PhD, President and CEO, will represent Precigen.

What is the purpose of Precigen's participation in the virtual symposium?

The participation aims to discuss advancements in oncology and highlight Precigen's innovative therapies.

Where can I find more information about Precigen's events?

More information can be found in the Events & Presentations section on Precigen's website.

What is the stock symbol for Precigen?

The stock symbol for Precigen is PGEN.